1. A modified release pharmaceutical composition comprising immediate release febuxostat granules in an amount ranging from about 20% to about 40% (w / w) of the total weight of the composition and delayed release febuxostat granules, soluble at pH values greater than or equal to 6.8, in an amount ranging from about 60% to about 80% (w / w) of the total weight of the composition, wherein said immediate release granules include (a) an inert core in an amount ranging from about 50% to about 55% (w / w) of the total mass of the immediate release granule, and (b) an immediate release layer that encapsulates an inert core containing a mixture of febuxostat and hydroxypropyl methyl cellulose in an amount ranging from about 45% to about 50 % (w / w) of the total mass of the immediate release granule, wherein the ratio of febuxostat to hydroxypropyl methylcellulose is in the range of about 1.5 to about 3； where indicated delayed release granules include (a) an inert core in an amount ranging from about 40.5% to about 43% (w / w) of the total weight of the delayed release granule, (b) an immediate release layer that encapsulates an inert core containing a mixture of febuxostat and hydroxypropyl methylcellulose in an amount ranging from about 35% to about 40% of the total weight of the delayed-release granule, where the ratio of febuxostat to hydroxypropyl methylcellulose is in the range of about 1.5 to about 3, (c) enterosol layer1. Фармацевтическая композиция с модифицированным высвобождением, включающая гранулы фебуксостата немедленного высвобождения в количестве в пределах от приблизительно 20% до приблизительно 40% (масс./масс.) от общей массы композиции и гранулы фебуксостата отсроченного высвобождения, растворимые при значениях рН, больших или равных 6,8, в количестве в пределах от приблизительно 60% до приблизительно 80% (масс./масс.) от общей массы композиции,где указанные гранулы немедленного высвобождения включают(a) инертное ядро в количестве в пределах от приблиз
